Tuesday, July 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Minimum wage a public health issue?

Some states, and perhaps soon the federal government, are considering increasing the minimum wage. President Joe Biden voiced his support for raising the federal minimum wage to $15 per hour while on the campaign trail, and also included it in his recent economic stimulus package. A ballot initiative in Florida to raise the statewide minimum by 2026 passed in November 2020. While discussions around raising the minimum wage typically center on the economic benefits and potential labor force impacts that would affect low-wage workers, there are also population health benefits to consider. These range from better physical and mental health outcomes to indirect influences on individual behaviors that affect health—but the existing research is limited at best. However, what we do know suggests that raising the minimum wage may not be uniformly helpful. Should policy makers pursue raising the minimum wage, it will be key to do so in a way that does not exacerbate long-standing inequities in both income and health.

 

Source: JAMA

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!